PT  - JOURNAL ARTICLE
AU  - Takagishi, Soh
AU  - Arimura, Koichi
AU  - Murata, Masaharu
AU  - Iwaki, Katsuma
AU  - Okuda, Tomohiro
AU  - Ido, Keisuke
AU  - Nishimura, Ataru
AU  - Narahara, Sayoko
AU  - Kawano, Takahito
AU  - Iihara, Koji
TI  - Protein Nanoparticles Modified with PDGF-B as a Novel Therapy After Acute Cerebral Infarction
AID  - 10.1523/ENEURO.0098-21.2021
DP  - 2021 Sep 01
TA  - eneuro
PG  - ENEURO.0098-21.2021
VI  - 8
IP  - 5
4099  - http://www.eneuro.org/content/8/5/ENEURO.0098-21.2021.short
4100  - http://www.eneuro.org/content/8/5/ENEURO.0098-21.2021.full
SO  - eNeuro2021 Sep 01; 8
AB  - Treatment options for cerebral infarction beyond the time window of reperfusion therapy are limited, and novel approaches are needed. PDGF-B is considered neuroprotective; however, it is difficult to administer at effective concentrations to infarct areas. Nanoparticles (NPs) are small and stable; therefore, we modified PDGF-B to the surface of naturally occurring heat shock protein NPs (HSPNPs) to examine its therapeutic effect in cerebral infarction. PDGF-B modified HSPNPs (PDGF-B HSPNPs) were injected 1 d after transient middle cerebral artery occlusion (t-MCAO) in CB-17 model mice. We analyzed the infarct volume and motor functional recovery at 3 and 7 d. PDGF-B HSPNPs were specifically distributed in the infarct area, and compared with HSPNPs alone, they significantly reduced infarct volumes and improved neurologic function 3 and 7 d after administration. PDGF-B HSPNP administration was associated with strong phosphorylation of Akt in infarct areas and significantly increased neurotrophin (NT)-3 production as well as reduced cell apoptosis compared with HSPNPs alone. Moreover, astrogliosis in peri-infarct area was significantly upregulated with PDGF-B HSPNPs compared with HSPNPs alone. Treatment with PDGF-B HSPNPs might be a novel approach for treating cerebral infarction.